Synthetic tuftsin-derived heptapeptide; investigational anxiolytic

Selank

aka TP-7 · Thr-Lys-Pro-Arg-Pro-Gly-Pro

Evidence grade
Grade C: Preliminary human data
for anxiety relief
User score everyone · n = 11
US FDA Not approved checked 2026-11-13
WADA 2026 Not named no clearance either · checked 2026-11-13
EU No data · checked 2026-11-13

Goals: Cognition & mood · Immune Compare with another peptide →

User reports

approximate — combined from two independent Reddit reads

Men 45–60

0 men aged 45–60

No reports in this group yet.

All men

1 man

small sample · n = 1

Outcome mixed 1 of 1

Benefits mood / anxiety 1 of 1

Side effects other 1 of 1

Stopped 0 of 1 Used with other compounds 1 of 1

Everyone

11 people

  • Positive: 6 of 11 (55%)
  • Mixed: 1 of 11 (9%)
  • Negative: 1 of 11 (9%)
  • No effect: 2 of 11 (18%)
Benefits reported of 11
Benefits reported (n = 11)
ItemReports
Mood / anxiety6 of 11 (55%)
Focus / cognition2 of 11 (18%)
Sleep2 of 11 (18%)
Side effects reported of 11
Side effects reported (n = 11)
ItemReports
Nausea1 of 11 (9%)
Other1 of 11 (9%)

Stopped 0 of 11 (0%) Used with other compounds 5 of 11 (45%)

User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.

In their words

  • “The only bad thing I can say about Selank is that it doesn't last long enough”

  • “The anxiety baseline is lower.”

  • “I feel much more relaxed throughout the entire day and it also seems to have made my sleep a bit better.”

  • “Last night was my first try with Selank, and I had no noticeable improvement with anxiety symptoms or sleep.”

  • “I have been on Selank and it good for Anxiety & GAD, Tried Oxytocin as well which was ok but wasn't amazing”

  • “As the title says I felt extreme nausea 3 hours after my morning SubQ dose My bottles are doses at 5mg selank/semax And 10mg PE22”

Read summaries and method notes

Read 1. No verified man aged 45–60 appeared in the coded Selank reports. The one explicitly male user was 21 and described improved social calm with a relatively short duration of effect and perceived tolerance. Across 10 coded users, the most common positive experience involved reduced anxiety or mental tension; some also mentioned better sleep or focus. Reported onset ranged from a few days to one or two months, while other users noticed no benefit or experienced nausea during a combined Selank, Semax, and PE-22-28 regimen. Five users combined Selank with other interventions, and the range of intranasal versus injected formulations limits comparability.

Read 2. No man aged 45–60 and no stated man. Two self-reports: one found Selank good for anxiety and GAD; one injected it with Semax and PE-22-28 and had severe nausea three hours later. Too small to establish patterns.

Note 1. Male sex was not inferred from interest in nootropics or the subreddit. Includes intranasal and subcutaneous reports without assuming equivalent exposure. One nausea account involved Selank, Semax, and PE-22-28 together. Other includes perceived tolerance or short-lived effects. Adamax experiences were not counted as Selank outcomes. Only selected accounts were coded and the absence of 45–60-year-old men is not evidence that no such users exist.

Note 2. Very limited thread availability; the only negative report involved Selank, Semax and PE-22-28 together.

Each read counted people independently. Overlap between the two reads is estimated from shared threads and removed; counts are approximate. How we count.

Summary

Synthetic tuftsin-derived heptapeptide investigated for anxiety. Small active-comparator studies report anxiolysis, but “outstanding,” broad cognitive benefit and freedom from sedation, addiction or withdrawal are not established clinical conclusions. Neurotransmitter-related gene changes and BDNF regulation are rat findings; they do not prove broad human immune support or clinical enhancement. Literature default is intranasal; SubQ is also used in community reports, but no verified subcutaneous regimen or clinical safety basis was found.

Safety

  • Potential immunogenicity from aggregation and peptide impurities
  • Reliable adverse-event incidence and long-term safety not established
  • No verified subcutaneous regimen or clinical safety basis found

From labels, regulators and trials. No signal in small studies ≠ safe.

Evidence C anxiety relief

C stands. Three small active-comparator studies with unclear randomization and no placebo arm. Russian registration for anxiety does not lift it, for the same reason as Semax, thymalin and DSIP.

Human trials · 4

  1. PMID 184540962008RCT (PubMed classification); randomization/blinding details not stated in abstract 62 people

    Generalized anxiety disorder and neurasthenia

    Similar reported anxiolysis versus medazepam; additional antiasthenic effects. Source

  2. PMID 251762612014Active-comparator clinical study; allocation unclear 60 people

    Anxiety-phobic and somatoform disorders

    Reported anxiolysis and mild nootropic effects versus phenazepam. Source

  3. PMID 263563952015Open-label randomized adjunct study; described as naturalistic/prospective in full text 70 people

    Anxiety-spectrum disorders

    Adjunct group reportedly improved earlier with fewer phenazepam-related adverse effects. Source

  4. PMID 323423182020Placebo-controlled exploratory imaging; total across Semax, Selank and placebo arms 52 people

    Healthy participants

    Amygdala connectivity changes; not a clinical anxiety or cognitive efficacy endpoint.

Bar length = trial size on a log scale.

Dose ranges

Reported ranges from labels and studies, with context. Not a recommendation.

  • clinical trial
    2.7 mg/day with phenazepam for 14 days; 20 adjunct-arm participants continued Selank for 7 further days; route not specified in reviewed methods Source on a non-primary host — not linked

Editorial ratings EDITORIAL

Editors’ judgement, 0–5. Opinion, not data; separate from grade and user score.

  • Safety 5 out of 5
  • Sleep 4 out of 5
  • Recovery 3 out of 5
  • Cognitive 4.5 out of 5

Sources

  1. pubmed.ncbi.nlm.nih.gov/18454096/
  2. pubmed.ncbi.nlm.nih.gov/25176261/
  3. pubmed.ncbi.nlm.nih.gov/26356395/
  4. fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-pres
  5. wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
  6. ema.europa.eu/en/medicines
  7. pubmed.ncbi.nlm.nih.gov/32342318/
  8. pubmed.ncbi.nlm.nih.gov/18841804/
  9. fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-c
  10. hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  11. pubmed.ncbi.nlm.nih.gov/26356395/?format=pubmed

Reddit threads read · 10

6 further sources on commercial or non-primary hosts not listed.

Research checked 2026-11-13.